Market Cap
$1.3B
IMTX
Immatics N.V.
$7.89 ▼ -6.55%
Prev close $8.44Market cap$1.3B
12-mo target$17.63 (+123.6%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on IMTX right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Insider Activity
$7.5M buy / $0.00 sell
Insider Net $
$7.5M
SEC Reports
10
Press Releases
6
Price chart 30d -17.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 28, 2026 ftd
Aug 27, 2026 SEC FTD: IMTX — 259,564 shares ($2.4M) failed to deliver
Settlement: 20260828, Price: $9.36, FTD Value: $2,429,519.04, IMMATICS N V ORD SHS (NLD)
Director Perceptive Advisors LLC purchased 863,060 shares of Immatics N.V. for $7.5M at $8.69/share in a single open-mar
INSIDER-BUY — Impact 6/10
Immatics N.V. completed a public offering of 15,535,100 ordinary shares and pre-funded warrants to purchase 4,315,304 or
6-K — Impact 6/10
Aug 26, 2026 Insider
Aug 18, 2026 SEC PERCEPTIVE ADVISORS LLC bought 863,060 shares
Director @ $8.69 ($7.5M)
Immatics reported Q2 2026 financial results showing a net loss of €62.5M ($71.2M) on collaboration revenue of €9.1M ($10
6-K — Impact 6/10
Aug 14, 2026 Insider
Pepin James Nelson was granted 181,200 shares
Gen Counsel and Corp Secretary
Aug 14, 2026 Insider
Jun 1, 2026 Press Pepin James Nelson was granted 43,800 shares
Gen Counsel and Corp Secretary
Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, sho
Impact 6/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| May 19, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Apr 28, 2026 | TD Cowen | INITIATE | Buy | 56% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Jun 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 7 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% |
Price targets
Where 6 covering analysts think IMTX trades over the next 12 months.
$17.63 +123.6% upside Strong Buy
Current$7.89 Low$11.80 Median$17.00 High$25.00 6 analysts
$11.80$25.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 4 bullish, 2 bearish, 2 mixed, 2 neutral · avg impact 6.1/10.Plus 6 press releases.
BULLISHINSIDER-BUY6/10
Director Perceptive Advisors LLC purchased 863,060 shares of Immatics N.V. for $7.5M at $8.69/share
Aug 27, 2026
BEARISH6-K6/10
Immatics N.V. completed a public offering of 15,535,100 ordinary shares and pre-funded warrants to p
Aug 26, 2026
NEUTRAL6-K6/10
Immatics reported Q2 2026 financial results showing a net loss of €62.5M ($71.2M) on collaboration r
Aug 18, 2026
MIXEDPRESS-RELEASE6/10
Immatics reported Q2 2026 earnings with a narrower-than-expected net loss per share of -$0.46 (€-0.4
Aug 18, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 28, 2026
ftd
FTD: IMTX — 259,564 shares ($2.4M) failed to deliver
Settlement: 20260828, Price: $9.36, FTD Value: $2,429,519.04, IMMATICS N V ORD SHS (NLD)
Aug 18, 2026
earnings
Immatics Announces Second Quarter 2026 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, August 18, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision tar
Aug 11, 2026
earnings_calendar
IMTX Q2 2026 Earnings Scheduled — 2026-08-11
Jun 1, 2026
announcement
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany , June 1, 2026 – <a href="https://www.globenewswire.com/Tracker?data=lEEf82PPB3W
May 31, 2026
announcement
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Houston, Texas and Tuebingen , Germany, May 31, 2026 – <a href="https://www.globenewswire.com/Tracker?data=ry-h
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.50 | $-0.54–$-0.44 | -3.2% | -1.3% | 3↑ 4↓ | $0.0B | 7 |
| Next Q | $-0.48 | $-0.56–$-0.35 | -42.5% | -5.0% | 3↑ 4↓ | $0.0B | 7 |
| Current FY | $-2.07 | $-2.35–$-1.91 | -10.6% | -7.0% | 2↑ 5↓ | $0.0B | 7 |
| Next FY | $-2.07 | $-2.46–$-1.63 | 0.1% | -9.1% | 1↑ 6↓ | $0.0B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.504 | — |
| 7d ago | $-0.512 | +0.009 |
| 30d ago | $-0.497 | -0.006 |
| 60d ago | $-0.497 | -0.006 |
| 90d ago | $-0.497 | -0.006 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 12 transactions. Net $7.5M — $7.5M bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | PERCEPTIVE ADVISORS LLC | Director | BUY | 863,060 | $8.69 | $7.5M |
| Aug 14, 2026 | Pepin James Nelson | Gen Counsel and Corp Secretary | AWARD | 181,200 | — | — |
| Aug 14, 2026 | Pepin James Nelson | Gen Counsel and Corp Secretary | AWARD | 43,800 | — | — |
| Jun 16, 2026 | Chambre Peter Alan | Director | AWARD | 48,000 | — | — |
| Jun 16, 2026 | Forster Eliot | Director | AWARD | 48,000 | — | — |
| Jun 16, 2026 | Carter Paul Rutherford | Director | AWARD | 48,000 | — | — |
| Jun 16, 2026 | ATIEH MICHAEL G | Director | AWARD | 48,000 | — | — |
| Jun 16, 2026 | Hothum Mathias | Director | AWARD | 48,000 | — | — |
| Jun 16, 2026 | Mason Heather L | Director | AWARD | 48,000 | — | — |
| Jun 16, 2026 | REICIN ALISE | Director | AWARD | 48,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for IMTX.
Shares short
4,438,234
Settlement Sep 15, 2026
Change vs prior
-8.6%
Semi-monthly cycle
Days to cover
8.3
At avg daily volume
Of shares outstanding
≈3.0%
Estimate — not % of float
All IMTX filing & press-release reports (16)
- INSIDER-BUY reportAug 27, 2026
- 6-K reportAug 26, 2026
- 6-K reportAug 18, 2026
- PRESS-RELEASE reportAug 18, 2026
- 6-K reportJun 2, 2026
- 6-K reportJun 1, 2026
- PRESS-RELEASE reportJun 1, 2026
- PRESS-RELEASE reportMay 31, 2026
- PRESS-RELEASE reportMay 30, 2026
- 6-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- 6-K reportApr 21, 2026
- PRESS-RELEASE reportApr 21, 2026
- 6-K reportApr 17, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportMar 5, 2026